Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: A retrospective investigation of 146 psoriasis patients

Journal of Dermatological Science

Volumn 76, Issue 3, 2014, Pages 180-185

  Hoffmann, Jochen H O ^a   Knoop, Christian ^a   Enk, Alexander H ^a   Hadaschik, Eva N ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Autoantibodies; Biomarkers; Psoriasis; TNF antagonist

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; METHOTREXATE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; ALOPECIA AREATA; ARTICLE; DISEASE ASSOCIATION; DRUG RESPONSE; EVENT FREE SURVIVAL; FEMALE; GROUPS BY AGE; HUMAN; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBSERVATIONAL STUDY; PREDICTION; PREDICTOR VARIABLE; PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RETROSPECTIVE STUDY; TUBERCULOSIS; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; PREDICTIVE VALUE;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919484929     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2014.09.003     Document Type: Article

References (17)

1. Nast A., Boehncke W.H., Mrowietz U., Ockenfels H.M., Philipp S., Reich K., et al. S3-guidelines for the treatment of psoriasis vulgaris update 2011. J. Dtsch. Dermatol. Ges. 2011, 9(Suppl 2):S1-S104.
2. National Institute of Health and Clinical, Excellence Psoriasis: assessment and management of psoriasis 2012, NICE.
3. Hoffmann J.H., Hartmann M., Enk A.H., Hadaschik E.N. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol 2011, 165:1355-1358.
4. Reich K., Burden A.D., Eaton J.N., Hawkins N.S. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012, 166:179-188.
5. Gniadecki R., Kragballe K., Dam T.N., Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011, 164:1091-1096.
6. Ortonne J.P., Chimenti S., Reich K., Gniadecki R., Sprogel P., Unnebrink K., et al. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J Eur Acad Dermatol Venereol: JEADV 2011, 25:1012-1020.
7. Leman J., Burden A.D. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. Br J Dermatol 2012, 167(Suppl 3):12-20.
8. Mazzotta A., Esposito M., Costanzo A., Chimenti S. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Am J Clin Dermatol 2009, 10:319-324.
9. Yukawa N., Fujii T., Kondo-Ishikawa S., Yoshifuji H., Kawabata D., Nojima T., et al. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. Arthritis Res Ther 2011, 13:R213.
10. Matsudaira R., Tamura N., Sekiya F., Ogasawara M., Yamanaka K., Takasaki Y. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol 2011, 38:2346-2354.
11. Lecluse L.L., Driessen R.J., Spuls P.I., de Jong E.M., Stapel S.O., van Doorn M.B., et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010, 146:127-132.
12. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005, 366:1367-1374.
13. Krieckaert C.L., Jamnitski A., Nurmohamed M.T., Kostense P.J., Boers M., Wolbink G. Comparing the long-term clinical outcome of etanercept and adalimumab treatment with respect to immunogenicity. Arthritis Rheum 2012, 64(12):3850-3855.
14. Romero-Mate A., Garcia-Donoso C., Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol 2007, 8:143-155.
15. Walters S.J. Consultants' forum: should post hoc sample size calculations be done?. Pharm Stat 2009, 8:163-169.
16. Menter A., Gordon K.B., Leonardi C.L., Gu Y., Goldblum O.M. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010, 63:448-456.
17. Augustin M., Spehr C., Radtke M.A., Boehncke W.H., Luger T., Mrowietz U., et al. German psoriasis registry PsoBest: objectives, methodology and baseline data. J. Dtsch. Dermatol. Ges. 2014, 12:48-57.